Do you really want to know my plan? If you do you can click
Do you really want to know my plan? If you do you can click on Goosebumbs and read my previous posts. It’s what I believe could happen and what I hope that happens.
As for being a follower. Never have been a follower. Been more of a leader in my adventures and groups. At the very least a team player.
I was a little hard on you and Bronxboy. But really I don’t believe in even friendly protests. I have been involved with letter campaigns and signature gathering before in my life and it was active but not a great way to get information out. Will those old methods change the world? I am not so old school that I believe they will change the world anymore.
If you really want to be active and supportive in this time in our life of social media. That is the place where information will go viral and effort is best placed in my opinion. Twitter and Facebook and Reddit and many other avenues will get you more progress. Writing government elected officials could help but my experience is a return of auto reply or form letters. Now if you commented on their Twitter as a follower of your local officials on the federal level then they might pay attention. But chances are they ignore you also. Someone will hopefully feel the passion at that level in government at some point to push for us. I don’t want to guess the chances of that. They seem pretty slim
Instead in this situation. I will hope for a 3 arm trial like what is predicted to happen to prove without a doubt that we will save lives. One arm for two doses and the second arm for 4 weekly doses with IV being the first dose for quick action. The third of coarse is placebo. I am hoping it is a 300 person trial with one third in each. With better age averaging and a 60 day trial with primary end point being 6 days early for out of hospital. Because that seems like a lock to achieve. That’s the bottom line. Meet your primary end point and we don’t have to beg for recognition when we can demand it. The hope is that the second arm shows mortality that is matching our 82% efficacy at 14 day mortality but at 28 days and even 60 days with no drop off. As being a secondary end point we take no risk if it’s a little less than what we hope. Then the celebration will happen... we no longer have to beg for a EUA because we will have had results enough to get the second BLA ever given for covid. The first of coarse was Remdesivir. That’s my dream and what I am waiting for. Is it achievable? I believe so or I would be here chatting daily.
Is there other way we succeed? Yes... there is another way but you will have to click on my posts from this last week to see the other way I believe we can get an EUA. I said I would not go there again. But really we need a BLA and if you know the difference between the two. You will know that another trial is necessary to achieve BLA status.
Some day I will start a post with... a long story short version. But that isn’t today. But you did ask. So that is my story... and in this situation you can make believe your in some way leading and you or I might get lucky. I should never doubt somebodies effort. It takes all of us to succeed. We just do it in different ways that suits our experience and needs.
If you can organize a protest and feel that passion enough to travel. Enjoy your effort and please accept my apology.
6
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Nod to Logistics and Beauty When beauty meets logistics, you end up with something like Capacity LLC making headlines in the 2026 BeautyMatter Awards. Now, I ain't one to usually get excited about anything involving freight and boxes, but this isn't just any nod in the 'Best Logistics Solution' category; it speaks volumes about where the beauty business is heading. Why...
Continue Reading
A Solid Performance from Piramal Pharma The numbers are in, and it's looking pretty good for Piramal Pharma Limited this time around. Their second quarter of fiscal year 2027 has seen some fireworks, and I'm not talking about some half-baked confetti deal. We're talking genuine growth and solid metrics here. Revenue and Profit Surge The headline? Revenue jumped a whopping...
Continue Reading
Deadline Extended for Kenvue's Noteholders In the wild world of corporate finance, the only thing more unpredictable than the weather is a boardroom decision. Kimberly-Clark (NASDAQ: KMB) just threw one such curveball by extending the deadline on their exchange offers for Kenvue Notes to November 2, 2026. Seems like 5 p.m. New York time is the new witching hour for this...
Continue Reading
A Rough Tumble for DICK'S Sporting Goods Let's cut to the chase: DICK'S Sporting Goods, Inc. (NYSE:DKS) just took a nosedive. We're talking a hard 30.68% fall on the stock, plummeting to $124.31 a share as of August 25, 2026. Now, if you were caught up in this whirlwind as an investor, you'd be forgiven for having a few choice words for the powers that be over at DICK'S....
Continue Reading
Judging by the latest buzz from La Vida's 2026 survey, the golden ticket for many US investors isn't a hot stock but something far more unexpected: the coveted 'Golden Visa.' Out of over 5,000 wealthy individuals invited to participate, 94.3% are mulling over a second residency or citizenship, and the big trigger? Political concerns. It's a clear sign that plenty of...
Continue Reading
What's Brewing at GeneDx? Looks like GeneDx Holdings Corp. is in some hot water—at least that's what Halper Sadeh LLC seems to think. Not your regular Tuesday at the exchange, folks. This legal eagle outfit is poking around GeneDx's henhouse, signaling possible breaches of fiduciary duties by their officers and directors. It's like catching a whiff of something fishy...
Continue Reading
BNY's CFO to Unpack Strategies at BMO Financials Conference They say you can tell a lot about a company by the folks steering the ship. And let me tell you, folks, Dermot McDonogh from BNY is setting sail over to Boca Raton to spill some beans. November 9 marks the date when BNY’s Chief Financial Officer will stand behind the mic at the BMO Financials Conference at 8:45...
Continue Reading
New Contender in the Global Botulinum Toxin Arena Launching a fresh player onto the international stage, CELSET INC. from Seoul throws down with SOLTOX, their own botulinum toxin Type A brand. This ain't your run-of-the-mill roll-out; it's another notch for Korean biotech trying to snag a piece of global market action. A Look at SOLTOX's Technical Makeup We’re talking...
Continue Reading
New Beginnings with Signature Wealth There's a fresh breeze blowing through Signature Wealth's Greenville office, and its name is Jennifer Sharp. Now, if you're meandering through financial landscapes, Sharp is the guide you didn’t know you needed—until now. With nearly 20 years under her belt, she brings a wealth of experience coupled with a knack for handling life's...
Continue Reading
The Bladder Cancer Scene: Steady as She Goes Sometimes, you look at numbers and find tranquility, like staring into still waters. That's the scene over at Photocure ASA with their latest Q3 results. Clocking in with revenues of NOK 134.2 million from their Hexvix®/Cysview® products, they're barely flinching from last year's NOK 134.1 million. Is it a victory or a...
Continue Reading
Top 5 Most Recently Viewed Articles
Nvidia Raises Concerns Over Legislative Changes NVIDIA Corp. (NASDAQ: NVDA) has expressed significant concerns regarding proposed legislation in Congress, which aims to limit its ability to sell chips globally. This comes in the wake of a recent export agreement between President Trump and NVIDIA that allows chip sales to China. The company argues that the new legislative...
Continue Reading
Olin Corporation Offers Updated Outlook for Fourth Quarter Olin Corporation (NYSE: OLN) has provided insights regarding its performance for the fourth quarter of 2025, indicating a significant deviation from its previous expectations. The latest forecast suggests an adjusted EBITDA of nearly $67 million, a notable decrease from the earlier anticipated range of $110 to...
Continue Reading
Raising Standards in Business Process Outsourcing Innovature BPO is making headlines with the recent appointment of Thoai Nguyen as Chief Operating Officer. This strategic decision reflects the company's ambition to enhance its operational effectiveness and continue providing exceptional service in outsourcing. With a commitment to integrating AI-driven solutions,...
Continue Reading
TCL and F-Secure Forge a Strategic Partnership TCL, renowned for its innovations in display technology, has recently proclaimed a robust alliance with F-Secure, a leader in cybersecurity. This strategic collaboration was unveiled during Network X 2025 and aims to bolster the security features in TCL's products across Fixed Broadband (FBB), Fixed Wireless Access (FWA), and...
Continue Reading
Introduction to the Aromatherapy Accessory In today's fast-paced world, finding ways to unwind and relax is essential for maintaining overall well-being. What if you could enjoy the calming effects of aromatherapy while staying cool? An innovative inventor from Crown Point, Indiana, set out to create a solution that combines the benefits of aromatherapy with the...
Continue Reading